Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

3(60.0%)

Phase 2

2(40.0%)

5Total

N/A(3)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04466007Phase 2Completed

Safety and Efficacy of Allogeneic Adipose Tissue Mesenchymal Stem Cells in Diabetic Patients With Critical Limb Ischemia

Role: collaborator

NCT05862025Not ApplicableUnknown

Evaluation of the Usefulness of Echocardiography in Patients With Staphylococcus Aureus Bacteremia (ET-AUREUS Study).

Role: collaborator

NCT05346029Not ApplicableUnknown

Role of Sarcopenia and Nutritional/Physical Therapy Intervention in Post-TIPS Hepatic Encephalopathy

Role: collaborator

NCT06058117Unknown

Paediatric European Group A Streptococcal United Study.

Role: collaborator

NCT04496336Completed

Non-invasive Substrate Evaluation in Atrial Fibrillation

Role: collaborator

NCT03773445Completed

Golimumab Trough Levels in Patients With Ulcerative Colitis

Role: collaborator

NCT01713725Phase 2Completed

Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria

Role: collaborator

NCT03201354Not ApplicableCompleted

Efficacy and Safety of the ExPRESS Implant Versus Deep Sclerectomy in Combined Surgery

Role: collaborator

All 8 trials loaded